Exploring the Cost-Utility of a Biomarker Predicting Persistent Severe Acute Kidney Injury: The Case of C-C Motif Chemokine Ligand 14 (CCL14).

Jorge EcheverriRui MartinsKai HarenskiJ Patrick KampfPaul McPhersonJulien TextorisJay L Koyner

Published in: ClinicoEconomics and outcomes research : CEOR (2024)

The analysis suggests that in the presence of an efficacious intervention preventing PS-AKI, identifying people at risk using CCL14 in addition to SOC is likely to represent a cost-effective use of resources.

Keyphrases

acute kidney injury
cardiac surgery
liver injury
liver fibrosis
randomized controlled trial
drug induced
early onset
data analysis